Department of Pulmonology, Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Respir Med. 2012 Oct;106(10):1376-82. doi: 10.1016/j.rmed.2012.06.007. Epub 2012 Jun 30.
Inhaled glucocorticosteroids reduce airway inflammation in asthma patients, thereby improving lung function and reducing airway hyperresponsiveness and symptoms. The response to glucocorticosteroids can be measured with the glucocorticosteroid skin-blanching test. We investigated if asthmatics have a lower skin-blanching response to glucocorticosteroids than non-asthmatic subjects and if asthmatics with airway obstruction have lower skin-blanching response than those without obstruction. Finally, we assessed which clinical and inflammatory parameters influence the variability in skin-blanching response.
We evaluated the skin-blanching response to topical budesonide in a large group of 315 well-characterized asthmatics and their relatives (asthma n = 114, healthy n = 140, other = 61).
The skin-blanching scores of the asthma probands and their healthy spouses were not significantly different. The skin-blanching score of patients with FEV(1) < 80% predicted was lower than of patients without obstruction. Lower skin-blanching score was significantly associated with lower FEV(1) %predicted, higher age, female gender, absence of allergy and summer season, but not with use of inhaled or oral glucocorticosteroids or packyears smoking.
Asthmatics do not have lower skin-blanching response to glucocorticosteroids than healthy subjects. Furthermore, lower skin-blanching response to glucocorticosteroids is associated with lower FEV(1), female gender, higher age and the absence of allergy.
吸入型糖皮质激素可减轻哮喘患者的气道炎症，从而改善肺功能并降低气道高反应性和症状。糖皮质激素的反应可以通过糖皮质激素皮肤发白试验来测量。我们研究了哮喘患者的糖皮质激素皮肤发白反应是否低于非哮喘患者，以及气道阻塞的哮喘患者的糖皮质激素皮肤发白反应是否低于无阻塞的患者。最后，我们评估了哪些临床和炎症参数影响糖皮质激素皮肤发白反应的可变性。
我们评估了大组 315 名特征明确的哮喘患者及其亲属（哮喘患者 n = 114，健康对照 n = 140，其他 n = 61）对布地奈德的皮肤发白反应。
哮喘患者及其健康配偶的皮肤发白评分无显著差异。FEV1 < 80%预计值的患者的皮肤发白评分低于无阻塞的患者。较低的皮肤发白评分与较低的 FEV1 %预计值、较高的年龄、女性性别、无过敏和夏季显著相关，但与吸入或口服糖皮质激素的使用或吸烟包年数无关。
哮喘患者对糖皮质激素的皮肤发白反应并不低于健康受试者。此外，糖皮质激素皮肤发白反应较低与较低的 FEV1、女性性别、较高的年龄和无过敏有关。
